Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market

CAMBRIDGE, Mass., October 05, 2026--Vyome Holdings, Inc. (Nasdaq: HIND) ("Vyome"), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today announced that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for U.S. Patent Application No. 17/787,303, titled "Formulations and Method for Treatment of Inflammatory Diseases."